A multi-institutional retrospective study of long-term PD-1 pathway inhibitor treatment for patients with non-small cell lung cancer (HOT1902)

A multi-institutional retrospective study of long-term PD-1 pathway inhibitor treatment for patients with non-small cell lung cancer (HOT1902) - HOT1902

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041403

Enrollment

300

Registered

2020-08-31

Start date

2019-12-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Advanced/Relapsed non-small cell lung cancer 2.Patients who received immune check point inhibitors between December 2015 and December 2017

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
1.Ratio of patients who can receive immune check point inhibitor for more than 1 year (long-term treatment patients) 2.Efficacy and safety of patients who can receive immune check point inhibitor for more than 1 year (long-term treatment patients)	—

Secondary

Measure	Time frame
Efficacy of ICI rechallenge treatment in long-term treatment patients after progression with prior ICI treatment	—

Countries

Japan

Contacts

Public ContactShotaro Ito

Hokkaido University Graduate school of Medicine Department of Respiratory Medicine, Faculty of Medicine

skyhigh0921@pop.med.hokudai.ac.jp011-706-5911

Outcome results